Despite their complexity, peptide amphiphile nanofibers offer a promising platform through which to deliver nanotherapeutics to treat cardiovascular disease. The future involves further development and evaluation of this technology in large animal models to strengthen translational data, discovery of additional physiologic targets, large scale standardized production, and incorporation of novel therapeutics. Importantly, we look forward to incorporating antioxidants into our existing PA nanofiber delivery vehicles to hopefully produce a synergistic effect of our targeted therapeutics.
Foley et al. (Sat,) studied this question.